Intralipid 20% (Synonyms: Intralipid) |
Catalog No.GB58896
One-Click Copy Product Info
|
Intralipid 20% is an intravenous 20% soybean oil fat emulsion. Intralipid 20% provides essential and non‑essential long‑chain fatty acids as energy substrates and participates in cell membrane composition.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 68890-65-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Intralipid 20% is an intravenous 20% soybean oil fat emulsion. Intralipid 20% provides essential and non‑essential long‑chain fatty acids as energy substrates and participates in cell membrane composition. Intralipid 20% also encapsulates lipophilic drug molecules through the lipid sink effect to reverse systemic toxicity caused by local anesthetics. Intralipid 20% can be used in studies related to parenteral nutrition support and rescue from local anesthetic systemic toxicity (LAST)[1-4].
In vitro, Intralipid 20% (0.02, 0.2mg/ml) was co‑treated with Paclitaxel in human breast cancer MDA‑MB‑231, non‑small cell lung cancer A549, pancreatic Panc1 cells and human monocytic THP‑1 cells for 3 days. Intralipid 20% did not significantly affect the 50% cytotoxic concentration of Paclitaxel in human breast cancer, non‑small cell lung cancer, or pancreatic cancer cells, but increased the 50% cytotoxic concentration of Paclitaxel in human monocytic THP‑1 cells by approximately 5‑fold, exerting a protective effect[5]. Intralipid 20% (diluted to 0.001%, 0.01%, 0.1%) was applied to human ovarian epithelial adenocarcinoma OVCAR‑3, Caov‑3, OVCAR‑8, and OVCAR‑5 cells for 72h. Intralipid 20% treatment reduced the survival fraction of OVCAR‑3 and OVCAR‑8 cells[6].
In vivo, Intralipid 20% (10ml/kg/h) combined with heparin (0.0975IU/min) was infused via the jugular vein into adult male Sprague‑Dawley rats for 6h. Intralipid 20% elevated plasma free fatty acid levels, decreased the glucose infusion rate, down‑regulated hepatic ApoM gene expression, and up‑regulated the hepatic mRNA levels of Acaca, Acox1, Akt1, Araf, G6pc, Irs2, Ldlr, Map2k1, and pyruvate kinase[7]. Intralipid 20% (4g/kg) was administered via percutaneous intraperitoneal injection through the abdominal wall into female Wistar rats. Intralipid 20% increased serum triglyceride and various fatty acid levels (16C, 18C, 18‑1C, 18‑2C), peaking at 6h post‑injection and showing a secondary peak after 15h[8].
References:
[1] Coulam CB. Intralipid treatment for women with reproductive failures. Am J Reprod Immunol. 2021 Apr;85(4):e13290.
[2] Kumar P, Marron K, Harrity C. Intralipid therapy and adverse reproductive outcome: is there any evidence? Reprod Fertil. 2021 Jun 3;2(3):173-186.
[3] Ollier M, Giles S, Gosselin S. The Occasional intralipid emulsion therapy. Can J Rural Med. 2023 Oct-Dec;28(4):195-200.
[4] Harsten R, Tetlow SJ, Chan T, et al. Intralipid and haemodialysis in caffeine overdose. BMJ Case Rep. 2020 May 14;13(5):e234256.
[5] Chen YJ, Tsai CY, Cheng YM, et al. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System. Sci Rep. 2020 Feb 18;10(1):2838.
[6] Overchuk M, Choi AM, Wiltshire GAE, et al. Beyond light scattering: the effects of intralipid on benzoporphyrin derivative-sensitized photodynamic treatment in ovarian cancer cells. J Biomed Opt. 2025 Dec;30(Suppl 3):S34116.
[7] Zheng L, Feng Y, Shi Y, et al. Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats. PLoS One. 2014 Aug 21;9(8):e105681.
[8] Moran J, Cruz G, Nogue-Rales F, et al. Transperitoneal absorption of intralipid in rats: total serum fatty acids and triglyceride after absorption. JPEN J Parenter Enteral Nutr. 1986 Nov-Dec;10(6):604-8.
| Cell experiment [1]: | |
|
Cell lines |
Human breast cancer MDA-MB-231 cells, non-small cell lung cancer A549 cells, pancreatic cancer Panc1 cells, human monocytic THP-1 cells, THP-1-derived M0/M1/M2 macrophages |
|
Preparation Method |
MDA-MB-231, A549, Panc1 were maintained in DMEM supplemented with 10% fetal bovine serum (FBS); THP-1 was maintained in RPMI1640 supplemented with 10% FBS. For cytotoxicity assay, cells were co-treated with serially diluted paclitaxel and Intralipid 20% (0.02, 0.2mg/ml) for 3 days via medium replacement. For macrophage experiment, THP-1 cells were first differentiated into M0 (induced by 50nM PMA for 48h), M1 (induced by 50nM PMA for 6h followed by 10pg/ml LPS + 20ng/ml IFN-γ for 48h), M2 (induced by 50nM PMA for 6h followed by 20ng/ml IL-4 + 20ng/ml IL-13 for 72h) macrophages, then incubated with Intralipid 20% for 3 days. |
|
Reaction Conditions |
0.02、0.2mg/ml; 3 days |
|
Applications |
Intralipid 20% did not significantly alter the 50% cytotoxicity concentration (CC50) of paclitaxel in MDA-MB-231, A549, Panc1 cells, but increased the CC50 of paclitaxel in THP-1 cells by approximately 5-fold. Intralipid 20% did not affect the endocytic capacity of M0, M1, M2 macrophages, and promoted polarization of M0 and M2 macrophages to M1-like phenotype: in M1 macrophages, expressions of M1 markers CD80 and CD215 were maintained, while expressions of M2 markers CD206 and CD163 were downregulated; in M0 and M2 macrophages, expressions of CD80 and CD215 were significantly upregulated by more than 2-fold, and CD206 and CD163 were obviously decreased. |
| Animal experiment [2]: | |
|
Animal models |
Adult male Sprague-Dawley (SD) rats |
|
Preparation Method |
SD rats were acclimatized for 1 week before surgery, then catheters were placed in two jugular veins (one for Intralipid infusion, the other for 20% glucose infusion during hyperinsulinemic-euglycemic clamp) and one carotid artery (for blood sampling), with 7-day recovery post-surgery. On the experimental day, 20% Intralipid combined with heparin was infused via the jugular vein for 6h; partial rats underwent synchronous hyperinsulinemic-euglycemic clamp: primed-constant insulin infusion (10mU/kg/min) was performed, 20% glucose infusion rate was adjusted to maintain blood glucose at ~5.5mM, and the mean glucose infusion rate (GIR) in the last 30min was recorded. Control rats received 5% glucose combined with the same dose of heparin. Rats were sacrificed after 6h infusion, blood was collected to measure plasma nonesterified fatty acid (FFA) levels, and livers were harvested for gene expression detection. |
|
Dosage form |
10ml/kg/h; intravenous infusion via jugular vein; 6h |
|
Applications |
Intralipid 20% increased plasma FFA levels by 17.6-fold, decreased GIR by 27.1% compared with the control group, downregulated hepatic ApoM gene expression by 40.4%, did not significantly alter hepatic PPARβ/δ mRNA expression, and significantly upregulated the hepatic mRNA levels of Acaca, Acox1, Akt1, Araf, G6pc, Irs2, Ldlr, Map2k1 and pyruvate kinase in SD rats. |
|
References: |
|
| Cas No. | 68890-65-3 | SDF | |
| Synonyms | Intralipid | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at 4°C, do not freeze. | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)